Ptc Therapeutics Stock Current Asset
| PTCT Stock | USD 43.23 0.34 0.79% |
PTC Therapeutics fundamentals help investors to digest information that contributes to PTC Therapeutics' financial success or failures. It also enables traders to predict the movement of PTC Stock. The fundamental analysis module provides a way to measure PTC Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PTC Therapeutics stock.
At this time, PTC Therapeutics' Other Current Assets are comparatively stable compared to the past year. Total Current Assets is likely to gain to about 1.3 B in 2024, whereas Non Current Assets Total are likely to drop slightly above 479.9 M in 2024. PTC | Current Asset |
PTC Therapeutics Company Current Asset Analysis
PTC Therapeutics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current PTC Therapeutics Current Asset | 355.95 M |
Most of PTC Therapeutics' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PTC Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
PTC Current Asset Historical Pattern
Today, most investors in PTC Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various PTC Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of PTC Therapeutics current asset as a starting point in their analysis.
PTC Therapeutics Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
PTC Total Assets
Total Assets |
|
In accordance with the recently published financial statements, PTC Therapeutics has a Current Asset of 355.95 M. This is 83.46% lower than that of the Biotechnology sector and 66.44% lower than that of the Health Care industry. The current asset for all United States stocks is 96.19% higher than that of the company.
PTC Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PTC Therapeutics' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PTC Therapeutics could also be used in its relative valuation, which is a method of valuing PTC Therapeutics by comparing valuation metrics of similar companies.PTC Therapeutics is currently under evaluation in current asset category among its peers.
PTC Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of PTC Therapeutics from analyzing PTC Therapeutics' financial statements. These drivers represent accounts that assess PTC Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of PTC Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.8B | 4.0B | 2.8B | 2.7B | 2.1B | 1.3B | |
| Enterprise Value | 2.5B | 4.2B | 2.5B | 3.0B | 3.7B | 3.9B |
PTC Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, PTC Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to PTC Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
PTC Fundamentals
| Return On Equity | -77.4 | ||||
| Return On Asset | -0.0515 | ||||
| Profit Margin | (0.50) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 2.72 B | ||||
| Shares Outstanding | 77.13 M | ||||
| Shares Owned By Insiders | 2.34 % | ||||
| Shares Owned By Institutions | 97.66 % | ||||
| Number Of Shares Shorted | 4.89 M | ||||
| Price To Earning | (5.67) X | ||||
| Price To Book | 1,743 X | ||||
| Price To Sales | 3.70 X | ||||
| Revenue | 937.82 M | ||||
| Gross Profit | 2.63 M | ||||
| EBITDA | (330.34 M) | ||||
| Net Income | (626.6 M) | ||||
| Cash And Equivalents | 288.43 M | ||||
| Cash Per Share | 4.01 X | ||||
| Total Debt | 2.23 B | ||||
| Current Ratio | 1.23 X | ||||
| Book Value Per Share | (13.70) X | ||||
| Cash Flow From Operations | (158.42 M) | ||||
| Short Ratio | 5.83 X | ||||
| Earnings Per Share | (5.94) X | ||||
| Price To Earnings To Growth | 0.81 X | ||||
| Target Price | 45.0 | ||||
| Number Of Employees | 988 | ||||
| Beta | 0.63 | ||||
| Market Capitalization | 3.33 B | ||||
| Total Asset | 1.9 B | ||||
| Retained Earnings | (3.28 B) | ||||
| Working Capital | 615.53 M | ||||
| Current Asset | 355.95 M | ||||
| Current Liabilities | 45.39 M | ||||
| Net Asset | 1.9 B |
About PTC Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PTC Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PTC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PTC Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for PTC Stock Analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.